These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 4773983)

  • 41. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M; Rojas P; Kravzov J; Rios C
    Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
    [No Abstract]   [Full Text] [Related]  

  • 42. [Action of L-dopa in Parkinson's syndrome].
    Ucar S; Eiras J
    Rev Clin Esp; 1971 Feb; 120(3):257-62. PubMed ID: 5568474
    [No Abstract]   [Full Text] [Related]  

  • 43. [L-dopa in Parkinson's syndrome].
    Filho RM; de Karam GM
    Rev Bras Med; 1971 May; 28(5):220-31. PubMed ID: 5563096
    [No Abstract]   [Full Text] [Related]  

  • 44. The metabolism of orally administered L-dopa in Parkinson patients.
    Cote LJ; Cohen G; Yahr MD
    Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of Parkinson's syndrome with L-dopa. In operated and nonoperated cases].
    Pimenta Ada M; Friguglietti DJ
    Rev Bras Med; 1971 Sep; 28(9):481-96. PubMed ID: 5139650
    [No Abstract]   [Full Text] [Related]  

  • 47. [Biochemistry and treatment of Parkinson's disease].
    Barbeau A
    Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 49. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
    Richard MG; Bennett JP
    Exp Neurol; 1994 Sep; 129(1):57-63. PubMed ID: 7925842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Use of the probenecid test for the diagnosis and treatment of Parkinsonism. Review of the literature and personal experience (author's transl)].
    Vanderheyden JE; Dekoninck WJ; Lefèvre A; Mendlewicz J
    Encephale; 1980; 6(4):349-66. PubMed ID: 6160034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 52. The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse.
    Pifl C; Giros B; Caron MG
    Adv Neurol; 1996; 69():235-8. PubMed ID: 8615133
    [No Abstract]   [Full Text] [Related]  

  • 53. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 54. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilites for the future.
    Hornykiewicz OD
    Neurology; 1970 Dec; 20(12):Suppl:1-5. PubMed ID: 5529913
    [No Abstract]   [Full Text] [Related]  

  • 55. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.
    Tomac A; Lindqvist E; Lin LF; Ogren SO; Young D; Hoffer BJ; Olson L
    Nature; 1995 Jan; 373(6512):335-9. PubMed ID: 7830766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. L-DOPA therapy in drug-induced parkinsonism evaluated by the method measuring the facial expression.
    Kimura N; Tsukue I
    Hiroshima J Med Sci; 1971 Mar; 20(1):55-63. PubMed ID: 5121129
    [No Abstract]   [Full Text] [Related]  

  • 57. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 58. An evaluation of L-dopa in Parkinson patients.
    Mones RJ
    Trans Am Neurol Assoc; 1969; 94():307-9. PubMed ID: 5374472
    [No Abstract]   [Full Text] [Related]  

  • 59. [Value of the probenecid test in the diagnosis and treatment of parkinson disease].
    Vanderheyden JE; Noel G; Mendlewicz J
    Acta Neurol Belg; 1982; 82(6):339-52. PubMed ID: 7164768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Nigrostriatal system as a source of torsion extrapyramidal disorders (review)].
    Arushanian EB; Dutov AA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(6):930-8. PubMed ID: 6774537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.